InSite Vision, Inc.

DUBLIN, May 10, 2023 /PRNewswire/ -- The "Global Antibiotics Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Antibiotics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering: Antibiotics Aminoglycosides Cephalosporin Clindamycin Macrolides Penicillin Quinolones Sulfonamides Tetracycline Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains over 340 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products. Report scope Global Antibiotics Partnering Terms and Agreements 2010 to 2023 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide. Global Antibiotics Partnering Terms and Agreements 2010 to 2023 includes: Trends in antibiotics dealmaking in the biopharma industry since 2010 Analysis of antibiotics deal structure Access to headline, upfront, milestone and royalty data Access to over 340 antibiotics deal records and contract documents where available The leading antibody deals by value since 2010 Most active antibiotics dealmakers since 2010 The leading antibiotics partnering resources In Global Antibiotics Partnering Terms and Agreements 2010 to 2023, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned Oxford Drug Design Gilead Sciences MD Anderson Cancer Center Biomedical Advanced Research and Development Authority Lysando Warp Drive Bio Centre for Drug Research and Development (CDRD) InSite Vision France's General Directorate for Armaments Q-linea AB Basilea Pharmaceutica European Commission European Union XBiotech QureTech Bio AnnaMed Dr. Reddy's Laboratories NovaMedica The Medicines Company The Regents of the University of California Paratek Pharmaceuticals Stiefel Laboratories Decibel Therapeutics NacuGen Therapeutics Quotient Bioresearch Emergent BioSolutions Novasep Polypeptide Laboratory Premier Inc Optimer Pharmaceuticals Auspherix Strides Arcolab Synthetic Biologics Medimetriks SINTEF Dana-Farber Cancer Institute Finorga Allergan For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

LOS ANGELES, Jan. 9, 2023 /PRNewswire/ -- Unio Health Partners ("Unio") a Triton Pacific Capital Partners ("Triton Pacific") portfolio company, is pleased to announce a partnership with inSite Digestive Health Care ("inSite"), which joins the platform as the fourth major division of Unio. Unio's partnership with inSite represents a significant expansion of its gastroenterology business and more than doubles the size of the platform. inSite's 67 gastroenterologists and three pathologists join Unio's 40 urologists, four gastroenterologists, four radiation oncologists, and pathologist as stakeholders in the preeminent multi-specialty physician services platform in the Western United States. With the inSite transaction, Unio now has 182 providers consisting of 119 physicians and 63 advanced practice providers operating out of 54 locations across Southern, Central, and Northern California. "In less than two years, we have partnered with five leading physician practices across California, not only adding considerable scale and density but also forging a sophisticated, fully integrated management services organization," said Marshal Salomon, Unio CEO. "We are focused on bringing together elite groups with diverse capabilities, augmenting them with new resources, and sharing best practices across the platform. The inSite physicians have built an impressive group and will be invaluable contributors to Unio's growth." Since its formation in 2012, inSite has delivered high-quality patient care as the largest independent digestive health platform in California. It offers a broad suite of services, including a full range of GI services and procedures, pathology, anesthesia, chronic care management, imaging, and clinical research. inSite is supported by a robust back office with centralized management services. Richard Kuritzkes, MD, Co-Managing Physician of inSite, commented: "Unio and inSite share a common mission of preserving independent private practice for physicians in California. Unio's values, goals, and approach align perfectly with ours: empowering physicians to provide exemplary patient care and enhance their practices via access to unparalleled management capabilities, expanded services, and a wealth of strategic expertise." Looking ahead to 2023, the inSite partnership provides strong momentum for Unio to continue expanding in both gastroenterology and urology. Unio seeks to affiliate with quality-oriented physician groups with a firm commitment to clinical excellence, evidence-based medicine, and compliance. With a scalable, fully built-out management services organization and dedicated investment team from Triton Pacific, Unio and its physician partners are poised for further growth. "The partnership between Unio and inSite will offer immense strategic benefits to both organizations and their affiliated physician practices," said Asia Brumwell, Triton Pacific Partner. "Gastroenterology and urology are highly complementary specialties, and the combined organization will be an early mover in the next phase of physician practice management expansion, creating compelling strategic opportunities and multi-dimensional avenues for growth. We are very pleased to partner with inSite and believe this both demonstrates and enhances Unio's value proposition to physician groups." Terms of the transaction were not disclosed. DLA Piper and Baird Investment Banking advised Triton Pacific/Unio. Katten Muchin Rosenman and Coker Capital advised inSite. About Unio Unio is a highly differentiated physician services platform established by Triton Pacific with the goal of transforming urology, gastroenterology, and radiation oncology care delivery across the Western United States. Unio partners with leading physician practices, creating a cohesive, quality-oriented clinical culture and facilitating best practice sharing across the platform. Unio's affiliated practices gain access to a broader suite of services, providing a meaningful benefit to both physicians and patients. Focusing initially on the fragmented Western U.S. landscape, Unio will continue to build significant size, scale, and geographic coverage that will enhance the platform's value proposition to all stakeholders. Unio was founded in 2021 with the acquisition of Genesis Healthcare Partners MSO and a partnership with Genesis Healthcare Partners physicians. Unio's best-in-class clinical program covers three sub-specialties (urology, gastroenterology, and radiation oncology) and offers numerous ancillary services, including pathology, in-office dispensing, anesthesia, imaging, clinical research, and chronic care management. Unio is led by a highly accomplished management team and provides a full suite of management services to its affiliated practices. Unio has a deep pipeline and expects to grow the platform to 200+ physicians within the next few years. About Triton Pacific Los Angeles-based Triton Pacific Capital Partners () has organized more than 50 private equity investment partnerships and a public, non-traded BDC and has completed 27 private equity transactions. Triton Pacific has a highly focused healthcare investment team with a demonstrated track record of successfully sourcing, acquiring, and managing healthcare investments. Unio is the healthcare team's ninth platform investment. SOURCE Triton Pacific

PHILADELPHIA, May 5, 2021 /PRNewswire/ -- Century Therapeutics, LLC, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Joe Jimenez as Board Chair and Cynthia Butitta as a new Independent Director. As former CEO of Novartis and current Co-Founder and Managing Partner of biotech venture firm Aditum Bio, Mr. Jimenez has extensive expertise in the biopharma industry driving innovation and leading companies at varying stages of development. Ms. Butitta is a veteran biotech executive specializing in corporate finance and strategic operations, most recently as the Chief Operating Officer and Chief Financial Officer of Kite Pharma. "Joe Jimenez and Cindy Butitta bring decades of leadership and proven records of success in the pharmaceutical and biotech industries to the Century board," said Lalo Flores, Chief Executive Officer of Century Therapeutics. "Their expertise will be invaluable as we continue to grow Century into a premier cell therapy company that dramatically and positively transforms the lives of patients suffering from life-threatening cancers." "During my time on Century's Board of Directors, I have been impressed by the company's strategic, vertically-integrated approach to overcoming many of the challenges associated with existing allogeneic cell therapies," said Mr. Jimenez. "The team's deep expertise in cell therapy and drug development, manufacturing, and commercialization uniquely positions them to lead the next phase of cell therapy and I am pleased to continue to support the company in my new role as board chair." Mr. Jimenez joined Century's Board of Directors in 2020. He previously served as Chief Executive Officer of Novartis. Under his leadership, Novartis won FDA approval for use of their CAR T cell therapy, Kymriah, to treat B-cell acute lymphoblastic leukemia and developed one of the largest pipelines of self-originated drugs in the biopharma industry. Mr. Jimenez's strong commitment to R&D resulted in transformation of the company's portfolio to focus on innovative and patent-protected medicines. Mr. Jimenez is also a member of the Board of Directors of General Motors Company, The Procter & Gamble Company, and Graphite Bio. Mr. Jimenez earned his B.S. in economics from Stanford University and his M.B.A. in marketing from the University of California, Berkeley's Haas School of Business. Ms. Butitta brings more than 25 years of experience informing corporate strategy and business development in the biotechnology and high technology sectors to the Century Board of Directors. Most recently, she served as the Chief Operating Officer and Chief Financial Officer of Kite Pharma where she was responsible for securing over $1 billion in capital and contributed to the extensive growth of the organization. Ms. Butitta was also critical in facilitating the company's acquisition by Gilead Sciences for approximately $11.9 billion in 2017. Prior to Kite Pharma, Ms. Butitta was the Senior Vice President and Chief Financial Officer of NextWave Pharmaceuticals until its acquisition by Pfizer in 2012. She has also held executive leadership roles at Telik, Inc., Connetics Corporation, and InSite Vision Inc. Ms. Butitta is currently an Independent Director at Olema Oncology, Autolus Ltd., and UroGen Pharma. She holds a B.S. in business and accounting from Edgewood College and received her M.B.A. in finance from the University of Wisconsin, Madison. "Century's proprietary iPSC based allogeneic cell platform technology offers the potential to treat a broad range of cancers by exploiting the distinct biologies of both NK and T cells," said Ms. Butitta. "I'm honored to join the Board of such a forward-thinking company during this critical period of growth and look forward to working with my fellow board members to help progress the company's pipeline of revolutionary cell therapies through the clinic to patients in need." About Century Therapeutics Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. For more information, please visit .